Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTC-DOX for Unresectable Hepatocellular Carcinoma
NCT00054951Phase 2Unknown
- Sponsor
- FeRx
- Start
- Jun 2001
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MTC-doxorubicin in hepatocellular carcinoma (HCC), sponsored by FeRx. Primary endpoint: Time to Disease Progression. Status: unknown.
02
Drugs
MTC-doxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00054951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00054951.